U.S. Stock Market News: Insmed surged on October 29 as revenue exceeded expectations, guidance was raised, and respiratory drug sales increased.

Insmed October 29 Surge Interpretation

Keywords: Revenue surpasses expectations, guidance raised, respiratory drug growth

1. On October 29, Insmed released its Q3 2026 financial report, with total revenue of $524.4 million, higher than the institutional expectation of $501.35 million; among them, BRINSUPRI revenue was $400.1 million, a 29% quarter-on-quarter increase, and ARIKAYCE revenue was $124.4 million, a 9% year-on-year increase.

2. On October 29, the company raised its FY2026 sales guidance from $1.7 billion–$1.87 billion to $1.81 billion–$1.87 billion, with the market estimate at $1.801 billion; it also raised the BRINSUPRI revenue guidance to $1.35 billion–$1.4 billion, and ARIKAYCE revenue guidance to $460 million–$470 million.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)